Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of in vivo immunomodulation

@article{Streetly2008AlternateDP,
  title={Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of in vivo immunomodulation},
  author={Matthew Streetly and Kylie Gyertson and Yvonne Daniel and Jerome Bernard Zeldis and Majid A. Kazmi and S. Schey},
  journal={British Journal of Haematology},
  year={2008},
  volume={141}
}
We previously reported that daily dose pomalidomide (CC‐4047), a thalidomide analogue, has excellent anti‐myeloma activity but is associated with myelosuppression and deep vein thrombosis. We report here a phase 1 study to determine the maximum tolerated dose (MTD) of pomalidomide at 1 mg, 2 mg, 5 mg and 10 mg on alternate days (ad). Twenty patients with relapsed myeloma were treated. Grade 4 neutropenia occurred in all patients receiving 10 mg and the MTD was defined as 5 mg ad. No thrombotic… 

Spotlight on pomalidomide: could less be more?

Toxicity of pomalidomide in the MM-003 trial, however, was considerable, with 60% of patients experiencing drug-related G3/4 toxicity, suggesting that for the majority of patients the 4 mg daily dosing schedule is too toxic, and that strategies to deliver reduced dose are of high practical relevance.

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Pomalidomide 4 mg per day on days 1 to 21 of each 28-day cycle, with or without dexamethasone (40 mg/week), has encouraging activity with manageable toxicity in RRMM, including those refractory to both lenalidomides and bortezomib.

Profile of pomalidomide and its potential in the treatment of myelofibrosis

In comparison with earlier immunomodulatory agents, pomalidomide was associated with an improved toxicity profile, with substantially lower rates of myelosuppression and neuropathy, which is of particular interest for future studies.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

  • M. LacyS. Hayman S. Rajkumar
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
The combination of pomalidomide and low-dose dexamethasone is extremely active in the treatment of relapsed multiple myeloma, including high response rates in patients refractory to other novel agents.

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma

Efficacy outcomes with pomalidomide plus low‐dose dexamethasone were consistent with those of previous studies, and the most frequently occurring grade ≥3 adverse events were neutropenia, anemia, lymphopenia, and pneumonia, consistent with previous studies.

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

The combination of pomalidomides and dexamethasone (Pom/dex) is highly active and well tolerated in patients with lenalidomide-refractory myeloma.

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

The efficacy and safety data presented here, along with data from other phase 2 trials, suggest that pomalidomide 4 mg per day on days 1 to 21 of 28 with dexamethasone should be investigated in future trials.

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

POM+LoDEX was effective and generally well tolerated and provides an important new treatment option for RRMM patients who have received multiple prior therapies.

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.

We performed a phase 1/2 trial to determine the maximum tolerated dose (MTD) of pomalidomide and to explore its efficacy when combined with cyclophosphamide-prednisone in relapsed/refractory myeloma
...

References

SHOWING 1-10 OF 47 REFERENCES

Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.

  • S. ScheyP. Fields A. Dalgleish
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
This is the first report demonstrating in vivo T-cell costimulation by this class of compound, supporting a potential role for CC-4047 as an immunostimulatory adjuvant treatment.

Antitumor activity of thalidomide in refractory multiple myeloma.

Thalidomide can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy, and is active against advancedMyeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bortezomib, a member of a new class of anticancer drugs, is active in patients with relapsed multiple myeloma that is refractory to conventional chemotherapy.

Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009).

  • D. WeberC. Chen R. Knight
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Considering the ease of oral administration, higher response rate, longer time to progression and overall survival benefit, the combination of lenalidomide-dexamethasone may very well represent the treatment of choice for early refractory or relapsing multiple myeloma.

A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

Thalidomide monotherapy achieved complete and partial responses in 29·4% of patients with relapsed or refractory multiple myeloma.

Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010).

Combination lenalidomide/Dex is a relatively well-tolerated and active oral regimen for patients with relapsed or refractory MM and the difference in TTP between the 2 arms surpassed the pre-specified O’Brien-Fleming boundary for superior efficacy.

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Lenalidomide is active and well tolerated in relapsed, refractory myeloma, with the 30-mg once-daily regimen providing the basis for future studies as monotherapy and with dexamethasone.

Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone

The evidence of significant variations of thrombomodulin values in the 1st month of therapy, which is considered to involve the highest risk of thROMbosis, might support a role for throm bommodulin in this complex mechanism.

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.

The majority of patients will develop peripheral neuropathy given sufficient length of treatment with thalidomide, and therapy should be limited to less than 6 months to minimize the risk of neurotoxicity.